Monopar Therapeutics Receives FDA Rare Pediatric Disease Designation for ALXN1840

Monopar Therapeutics received Rare Pediatric Disease designation for ALXN1840 treating Wilson disease. This grants potential eligibility for a Pediatric Priority Review Voucher upon NDA approval.